NCT05576792View on ClinicalTrials.gov

A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China

CompletedOBSERVATIONAL
Enrollment

62

Participants

Timeline

Start Date

January 13, 2023

Primary Completion Date

July 10, 2024

Study Completion Date

July 10, 2024

Conditions
Retinopathy of Prematurity
Interventions
OTHER

Ranibizumab

Prospective observational study. There is no treatment allocation. Patients prescribed with ranibizumab 0.2 mg in the commercial setting are eligible to enroll into this study.

Trial Locations (1)

510000

Novartis Investigative Site, Guangzhou

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY